[Complementary scintigraphic examinations (99mTc-MDP, 99mTc-MIBI and Octreoscan) in breast neoplasm assessment].
Scintigraphic imagery was used in breast carcinoma mostly for the bone metastases screening, using 99mTc-MDP. Others radiopharmaceuticals can be used to visualize either the primary tumour or the soft tissues metastases. It's mainly the case of 99mTc-MIBI, and also of some somatostatin analogues, like Octreoscan. This case report of a patient with a T3N1M+ breast adenocarcinoma having different secondary sites represent also a prove of the complementarity of these explorations, which give the possibility of diagnostic and therapeutic evaluation and, in the same time, the possibility of a better understood of the metastasizing mechanism.
Stefănescu
C
C
U.M.F. Gr. T. Popa, Facultatea de Medicină, Dept. Biofizică şi Medicină Nucleară, Iaşi.
Chossiere
L
L
Rusu
V
V
Meignan
M
M
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000473:pathology; D000465:Algorithms; D001940:Breast / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000031:analogs & derivatives*; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate; D017256:Technetium Tc 99m Sestamibi
D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; C071632:SDZ 215-811; D004369:Pentetic Acid; D017256:Technetium Tc 99m Sestamibi; D015282:Octreotide; D013669:Technetium Tc 99m Medronate
Explorări scintigrafice complementare (99mTc-MDP, 99mTc-MIBI şi Octreoscan) în evaluarea neoplasmului mamar.